scholarly journals Safety of bisphosphonate use in hematopoietic progenitor cell transplantation in multiple myeloma patients

2005 ◽  
Vol 11 (2) ◽  
pp. 90
Author(s):  
S. Mazj ◽  
N. Ng ◽  
S.M. Lichtman ◽  
V. John ◽  
C. Devoe ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Cell Transplantation ◽  
Progenitor Cell ◽  
Hematopoietic Progenitor Cell ◽  
Hematopoietic Progenitor

scholarly journals Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma

Cancer ◽  
2006 ◽  
Vol 106 (10) ◽  
pp. 2171-2180 ◽  
Author(s):  
Brett T. Brinker ◽  
Edmund K. Waller ◽  
Traci Leong ◽  
Leonard T. Heffner, Jr. ◽  
Istvan Redei ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Overall Survival ◽  
Maintenance Therapy ◽  
Cell Transplantation ◽  
Progenitor Cell ◽  
Hematopoietic Progenitor Cell ◽  
Hematopoietic Progenitor

Disparities in Utilization of Autologous Hematopoietic Progenitor Cell Transplantation for Multiple Myeloma in the US

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 557-557
Author(s):  
Luciano J Costa ◽  
Jia-Xing Huang ◽  
Parameswaran N. Hari
Keyword(s):  
Multiple Myeloma ◽  
Cell Transplantation ◽  
Progenitor Cell ◽  
Conflicts Of Interest ◽  
Hematopoietic Progenitor Cell ◽  
Hematopoietic Progenitor ◽  
Pronounced Increase ◽  
Race Ethnicity ◽  
Sex Disparity ◽  
Racial Ethnic

Abstract Introduction: Autologous hematopoietic progenitor cell transplantation (AHPCT) is an established modality in the treatment of patients with multiple myeloma (MM) with impact in depth and duration of remission and, in some studies, overall survival. Utilization of AHPCT for treatment of MM in US is increasing but still low. Race-ethnicity, sex and age-disparities may affect AHPCT utilization, although they do not impact benefit from AHPCT. Methods: MM incidence derived from Surveillance, Epidemiology and End Results (SEER-18) database and AHPCT for MM reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) between 2005-2009 were analyzed. Cases were grouped in 4 racial-ethnic categories (REC): non-Hispanic Whites (NHW), non-Hispanic Blacks (NHB), Hispanics (irrespective of race) and Asians. We assessed utilization as the ratio between first AHPCT for MM and number of newly diagnosed cases in the period of interest and calculated the relative utilization ratio (RUR), as [utilization for a given category] / [utilization for the entire population]. Results: Data was obtained from 22,462 actual MM cases reported to SEER and 13,311 actual AHPCT reported to CIBMTR. NHW, NHB, Hispanics and Asians corresponded respectively to 72.0%, 18.7%, 6.7% and 2.6% of the new MM cases and 77.4%, 15.85, 5.2% and 1.6% of the AHPCT procedures. Median age at diagnosis of MM was higher in NHW (P=0.0002)and was higher in women than in men in all RECs. Age-adjusted RUR was 1.17 (95% C.I. 1.15-1.19) among NHW, higher than in NHB [0.69 (95% C.I. 0.67-0.72), P<0.0002], Hispanics [0.64 (95% C.I. 0.60-0.69), p<0.002] and Asians [0.65 (95% C.I. 0.58-0.73), P<0.0002]. There was higher utilization of AHPCT in men than in women detected among Hispanics (age adjusted RUR 0.72 vs 0.56, P=0.007), but not among NHW, NHB or Asians. Only 3.1% of the NHW patients younger than 65 were identified as uninsured vs. 8.1% of NHB, 11.9% of Hispanics and 3.2% of Asians (P<0.0001). Correction of sex disparity would lead to an overall increase of 1.3% in AHPCT for MM, higher among Hispanics (11.7%) but lower in the other categories (Figure, panel a). The hypothetical correction of racial-ethnic disparity would result in 15.9% increase in volume of AHPCT, with a pronounced increase among NHB, Hispanics and Asians (Figure, panel b). Increase in age at transplant will strongly affect AHPCT volumes with dissimilar impact in different RECs according to their age structure (Figure, panel c). Conclusions: Race-ethnicity disparity greatly affects AHPCT utilization for management of MM in US. Sex disparity plays a much lesser role, except among Hispanics. The profound age disparity is decreasing over time and will likely continue to drive major increase of AHPCT activity. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Hematopoietic Progenitor Cell Transplantation in Multiple Myeloma

1995 ◽  
Vol 18 (6) ◽  
pp. 518-523
Author(s):  
H. Goldschmidt ◽  
U. Hegenbart ◽  
R. Haas ◽  
W. Hunstein
Keyword(s):  
Multiple Myeloma ◽  
Cell Transplantation ◽  
Progenitor Cell ◽  
Hematopoietic Progenitor Cell ◽  
Hematopoietic Progenitor

scholarly journals Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program

2012 ◽  
Vol 12 (11) ◽  
pp. 1449-1462 ◽  
Author(s):  
Massimo Martino ◽  
Mauro Montanari ◽  
Benedetto Bruno ◽  
Giuseppe Console ◽  
Giuseppe Irrera ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Cell Transplantation ◽  
Progenitor Cell ◽  
Hematopoietic Progenitor Cell ◽  
Hematopoietic Progenitor ◽  
Outpatient Program

scholarly journals Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma

2008 ◽  
Vol 43 (2) ◽  
pp. 169-177 ◽  
Author(s):  
W R Drobyski ◽  
P Hari ◽  
C Keever-Taylor ◽  
R Komorowski ◽  
W Grossman
Keyword(s):  
Multiple Myeloma ◽  
Cell Transplantation ◽  
Progenitor Cell ◽  
Hematopoietic Progenitor Cell ◽  
Hematopoietic Progenitor
Sign in / Sign up

Export Citation Format

Share Document